Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Apr;11(2):113-6.
doi: 10.1111/j.1440-1797.2006.00547.x.

Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy

Tanqi Lou  1 , Cheng Wang, Zhujiang Chen, Chenggang Shi, Hua Tang, Xun Liu, Peida Yin, Xueqing Yu
Affiliations
Randomized Controlled Trial

Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy

Tanqi Lou et al. Nephrology (Carlton). 2006 Apr.

Abstract

Aim: To investigate the effect of leflunomide for treatment of immunoglobulin A (IgA) nephropathy.

Methods: Sixty IgA nephropathy patients were divided into two groups at random. Patients in the test group received leflunomide and patients in the control group received fosinopril. Clinical data were obtained at weeks 2, 4, 6, 8, 12, 16, 20, 24 and 28.

Results: The complete remission rate was 62.1% and the total effectiveness rate was 72.4%. In the leflunomide group, proteinuria significantly decreased from 1.66 +/- 0.42 g to 0.60 +/- 0.68 g (P < 0.05). The efficacy rate of leflunomide compared with fosinopril in treating IgA nephropathy was not statistically different (P > 0.05). Side-effects were mild in both treatment groups.

Conclusion: These preliminary results are encouraging, but further randomised studies are required before leflunomide can be recommended for the treatment of IgA nephropathy.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources